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1250 The Journal of Thoracic and CardObjective: Left ventricular reconstruction is performed in patients with ischemic
cardiomyopathy and akinetic or dyskinetic left ventricular regions. These patients
may remain at risk for malignant ventricular arrhythmias and hence may benefit
from prophylactic implantable cardioverter-defibrillators. Specific guidelines for
electrophysiologic testing and implantable cardioverter-defibrillator implantation in
patients undergoing left ventricular reconstruction are lacking. We aimed to assess
the residual risk and timing of ventricular arrhythmias after left ventricular recon-
struction to determine whether electrophysiologic risk stratification or implantable
cardioverter-defibrillator implantation can be safely deferred.
Methods: Data were prospectively gathered on 217 consecutive patients with left
ventricular ejection fractions less than 40% undergoing left ventricular reconstruction
at our institution from 1997 to 2002. Patients were divided into 3 groups: group 1,
implantable cardioverter-defibrillator present before surgery; group 2, implantable
cardioverter-defibrillator implanted early after surgery; and group 3, no implantable
cardioverter-defibrillator implanted. End points were all-cause mortality (censored
for cardiac transplantation) and appropriate implantable cardioverter-defibrillator
therapies.
Results: Of 217 patients (mean age, 61  10 years [mean  SD]), survival after a
median follow-up of 381 days was 90%. Electrophysiologic studies successfully iden-
tified patients at low risk. Appropriate implantable cardioverter-defibrillator therapies
occurred in 20% of group 1 and 12% of group 2. The median time to the first
implantable cardioverter-defibrillator therapy from the time of left ventricular recon-
struction was 43 days, and most first therapies (67%) occurred within the first 63 days.
Conclusions: The early event rates (occurring in the first 90 days after left ventricular
reconstruction) support the use of predischarge electrophysiologic studies, implantation
of implantable cardioverter-defibrillators before discharge from the hospital, or both.
Left ventricular reconstruction (LVR), or the modified Dor procedure, hasbeen performed with increasing frequency in patients with severe ischemicheart disease, ventricular dysfunction, and heart failure. However, its long-
term efficacy remains to be established and is the subject of the STICH (Surgical
Treatments for IsChemic Heart Failure) trial, which will compare medical therapy
with coronary artery bypass grafting (CABG) alone and CABG in addition to LVR
surgery.1 Although these approaches are intended to reduce mortality due to
coronary ischemia or heart failure, patients may remain at risk for mortality due to
life-threatening arrhythmias.
Patients who have undergone recent cardiac operations have been excluded in
some of the major trials examining the benefit of early arrhythmia risk stratification,
implantable cardioverter-defibrillator (ICD) therapy, or both. The Multicenter Un-
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fits for ICD implantation in ischemic cardiomyopathy with
nonsustained ventricular tachycardia and inducible sus-
tained ventricular arrhythmias, did include patients 4 days
after surgery. However, the Multicenter Automatic Defibril-
lator Implantation Trial (MADIT), which reported that ICD
therapy improved survival in patients with prior myocardial
infarction and left ventricular dysfunction, excluded pa-
tients within 2 months (MADIT) or 3 months (MADIT II)
after CABG.2,3 Furthermore, the Centers for Medicare &
Medicaid Services state that an ICD is reasonable and
necessary in patients with a left ventricular ejection fraction
(LVEF) less than 30%, but only after 3 months have elapsed
since operation.4 There are no clear guidelines regarding the
necessity of early ICD implantation in patients undergoing
LVR.
We used a customized, prospective database to assess (1)
the risk of ventricular arrhythmias after LVR and (2) the
timing of events after LVR to determine whether electro-
physiologic (EP) risk stratification or ICD implantation are
warranted before hospital discharge.
Methods
Patient Population
Patients were selected for LVR as part of a comprehensive non-
transplantation surgical approach to their heart failure syndrome.5
In practice, patients were assessed by cardiac magnetic resonance
imaging and 2- and 3-dimensional echocardiography in addition to
left ventriculography and coronary angiography. Consideration for
LVR was undertaken in patients whose myocardial scar was con-
fined to a single coronary territory (almost always the left anterior
descending artery). The final decision to perform LVR was made
by the surgeon at the time of operation. Data were prospectively
recorded in a customized database on consecutive patients under-
going LVR in our institution from 1997 to 2002. The database was
approved by the Institutional Review Board of the Cleveland
Clinic Foundation. Patients who survived until hospital discharge
and, thus, were eligible for EP testing were included for analysis.
The intent was for all patients to undergo EP studies, at the
discretion of the treating physician. When they were not per-
formed, it was largely due to patient refusal or logistic reasons.
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
EP  electrophysiologic
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
LVR  left ventricular reconstruction
MADITMulticenter Automatic Defibrillator
Implantation Trial
STICH  Surgical Treatments for IsChemic Heart
FailurePatients were excluded for any of the following reasons: emer-
The Journal of Thoracicgency operation, preoperative inotropic dependence, or preopera-
tive LVEF greater than 40%.
Surgical Technique
The rationale for and description of LVR are described elsewhere6;
LVR was performed primarily for anterior myocardial scarring.7
Briefly, the procedure was performed with cardiopulmonary by-
pass, and coronary revascularization, where needed, was per-
formed initially, followed by mitral valve annuloplasty through a
left atriotomy if there was significant mitral regurgitation. After
revascularization and mitral valve repair, LVR was performed.
The left ventricle was opened through the apical scar, and palpa-
tion with or without intraoperative echocardiography was used to
define the border zone between infarcted and normal myocardium.
A purse-string polypropylene suture was placed and tied through
this border zone to create a neck. Although the original description
of the procedure includes an endoventricular Dacron (DuPont,
Wilmington, Del) patch to exclude the infarcted myocardium from
the left ventricular cavity, in most cases LVR was accomplished
by the placement of additional sutures, without a Dacron patch.
Cryoablation was performed in 13% of patients. At the time of
operation, the presence of scarring (dyskinesis) or an akinetic
region was adjudicated by the surgeon, rather than by imaging
modalities.
EP Testing
EP testing was performed on most patients before discharge, at the
discretion of the treating physician. The EP study was performed
with patients in the fasting state by using programmed ventricular
stimulation. The stimulation protocols consisted of programmed
ventricular stimulation with either (1) up to 3 ventricular extra-
stimuli, after 8-beat paced drive cycles at up to 2 paced cycle
lengths at 2 right ventricular endocardial sites,8-11 or (2) 4 extra-
stimuli at 3 paced cycle lengths at 2 right ventricular sites.12 Burst
pacing, short-long-short coupling intervals, or both were also
performed in some patients. The specific stimulation protocol was
at the discretion of the physician. A positive study was defined as
inducible sustained ventricular tachyarrhythmias (monomorphic or
polymorphic) lasting more than 30 seconds or associated with
syncope, hemodynamic compromise, or the necessity for interven-
tion for termination. A negative EP study was defined as nonin-
ducibility of sustained ventricular tachyarrhythmias. The decision
to implant an ICD was made on the basis of late (48 hours)
documented life-threatening ventricular arrhythmias after LVR
(secondary prevention of sudden cardiac death) or for a positive
EP study (primary prevention).
Follow-up and End Points
Demographic, echocardiographic, clinical status, and ICD interro-
gation data were collected. All patients with ICDs underwent
regular scheduled device checks in the arrhythmia device clinic.
Survival status was obtained from the Social Security Death Index,
physician follow-up, review of medical records, or patient contact.
End points were all-cause mortality and appropriate ICD therapies.
ICD therapies were obtained from device interrogation and adju-
dicated as being appropriate by an electrophysiologist. When a
death occurred, every effort was made to ascertain the cause of
death. The World Health Organization definition of sudden cardiac
and Cardiovascular Surgery ● Volume 130, Number 5 1251
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CDdeath was used: “an unexpected death due to cardiac problems
which occurs within 1 hour from the start of any cardiac related
symptoms.”
Statistical Analysis
Patients were divided into 3 groups on the basis of ICD status:
group 1 had an ICD in situ before surgery, group 2 had an ICD
implanted after surgery, and group 3 had no ICD implanted (Figure
1). Survival is presented according to the method of Kaplan and
Meier. For survival analysis, patients who underwent orthotopic
cardiac transplantation were censored at the date of transplanta-
tion. Survival curves were compared by the log-rank test. Cox
proportional hazards methodology was used to assess the effect of
independent variables on survival or ICD discharge. The Kruskal-
Wallis test was used for comparisons of continuous variables, and
the 2 test was used to test for comparisons of categorical vari-
ables. Unless stated otherwise, data are expressed as mean  SD.
Results
Patient characteristics are shown in Table 1. Of 219 patients
undergoing LVR, 217 survived to hospital discharge and
were included in the analysis. The mean age of the overall
cohort (n  217) was 61  10 years (range, 29-83 years).
Most patients (82%) were male, 28% had diabetes, and 48%
had hypertension. Concomitant CABG was performed in
88%, 46% underwent mitral valve repair, cryoablation was
performed in 13%, and a patch was applied in 16% overall.
The types of surgery performed in the 3 groups were sim-
ilar, with the exception of cryoablation, which was more
commonly performed in group 1 as a result of the higher
incidence of preoperative ventricular arrhythmias in these
patients. At operation, 67% had dyskinetic scars, and 33%
had akinetic regions as determined by the surgeon. No
patient required cardiac transplantation before discharge.
During the follow-up period, 4 patients subsequently under-
went cardiac transplantation (2 from group 1 and 2 from
Figure 1. Description of the 3 groups. LVR, Left ventricul
EP, Electrophysiologic; Pre-op, before surgery; Post-Op, agroup 2).
1252 The Journal of Thoracic and Cardiovascular Surgery ● NovOf the 217 patients included in the study, 104 were
discharged with an ICD (Figure 1). Thirty patients (group 1)
had ICDs in situ before undergoing operation. After LVR,
indications for ICD implantation were secondary prevention
in 28 patients and primary prevention in 46. For the 28
patients who received an ICD for secondary prevention, the
qualifying arrhythmia occurred before surgery in 8 and after
surgery in 20. Four patients with negative EP studies had
ICD implantation performed because of late (48 hours)
life-threatening ventricular arrhythmias after LVR.
Of the 113 patients who did not receive an ICD, 46
patients did not undergo EP study. The decision of whether
to refer a patient for EP study was at the discretion of the
treating physician. The intent was for all patients to undergo
EP testing. However, patient refusal and logistical issues
prevented this on some occasions. Of the patients in groups
2 and 3, 113 patients had an EP study, and 48 (42%) were
positive; 2 patients with positive EP studies refused ICD
implantation (Figure 1).
There were significant differences among the 3 groups
(Table 1). Patients in group 1 were the sickest cohort, with
the highest percentage (80%) of dyskinetic scars, the largest
end-diastolic dimensions, the most frequent requirement for
mitral valve surgery, and the lowest proportion of concom-
itant revascularizations. Furthermore, group 1 had longer
QRS durations on their resting electrocardiograms, and
there was a trend for them to be older. Cryoablation was
performed more frequently in group 1 than in groups 2 or 3;
this is indicative of the incidence of ventricular arrhythmias
in patients who had ICDs before undergoing LVR.
The median follow-up was 381 days (range, 6-1601
days). Follow-up was complete in all patients. Annualized
mortality was 7.14%/y in group 1 and was significantly
lower in groups 2 (0.03%/y) and 3 (0.06%/y; P  .04).
construction; ICD, implantable cardioverter-defibrillator;
surgery.ar re
fterOverall survival was 90%. Compared with group 1, survival
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and 3 (P  .001), which had similar survival curves at 1 year
(Figure 2). In patients with a preoperative ICD (group 1), 6
(20%) of 30 patients died, and among the remaining cohorts
(groups 2 and 3), 14 (8%) of 187 patients died (P  .03). The
causes of death were available for 18 (90%) of 20 patients and
are shown in Table 2. Most patients died from progressive
myocardial failure, and 2 patients died from malignancy.
One sudden death occurred in group 1. The survival be-
tween EP and EP patients was similar (Figure 3).
In patients who were discharged from the hospital with
ICDs in situ, 6 (20%) patients in group 1 and 9 (12%) in
group 2 had appropriate ICD therapies. Overall, the inde-
pendent predictors of ICD therapy included preoperative
left ventricular end-diastolic dimensions (relative risk, 2.92;
95% confidence interval, 1.22-7.19; P  .02), left ventric-
ular end-systolic dimensions (relative risk, 2.61; 95% con-
fidence interval, 1.24-5.94; P  .02), LVEF (relative risk,
TABLE 1. Clinical characteristics, perioperative data, and
Variable
All
patients
n 217
Preoperative patient characteristics
% Male 82
Age (y) 61 10
Hypertension (%) 48
Diabetes (%) 28
Amiodarone (%) 39
LVEF (%) 22 8
LVEDD (cm) 6.4 0.9
LVESD (cm) 5.1 1.0
QRS (ms) 123 32
Dyskinetic scar (%) 67
NYHA class (%)
I 3
II 29
III 47
IV 21
Operative procedure
CABG (%) 88
Mitral valve surgery (%) 46
Patch (%) 16
Cryoablation (%) 13
End points
Follow-up, d (median  IQR) 381 660
Deaths, n (%) 20 (9)
Transplantation (n) 4
ICD therapy, n (%) N/A
Data are mean SD unless otherwise noted. LVEF, Left ventricular ejection
end-systolic dimension; NYHA, New York Heart Association; CABG, corona
defibrillator; N/A, not applicable.0.89; 95% confidence interval, 0.79-0.99; P  .03), and
The Journal of Thoracicconcomitant CABG (relative risk, 0.51; protective; 95%
confidence interval, 0.30-0.91; P  .03). Four patients,
despite a negative EP study, received ICDs for secondary
prevention. Of these, none received ICD therapy.
The 9 therapies delivered in group 2 included antitachy-
cardia pacing in 3 and shocks in 6. EP studies were highly
sensitive in predicting ICD therapies—8 of 9 therapies were
delivered to patients with positive studies, whereas 1 patient
who received multiple therapies had secondary prevention
as the indication for ICD.
The median time to first ICD therapy was 43 days
(Figure 4). Most (67%) first therapies occurred within the
first 63 days. In group 2, which had ICDs implanted after
LVR, the first arrhythmia occurred 13 days after surgery,
and two thirds of first events occurred within 63 days.
Discussion
This study demonstrates that patients remain at high and
omes for all patients and specified subgroups
Group P value
between
groups1 2 3
30 74 113
80 86 80 .47
 9 59 10 62 9 .11
43 45 52 .50
10 30 31 .07
63 54 23 .01
 8 22 6 23 8 .01
 0.8 6.4  0.8 6.3  0.9 .03
 1.0 5.2  0.9 4.9  1.0 .03
 36 122 31 114 25 .01
80 68 67 .24
0 1 4
13 30 3
43 55 43
43 14 20 .01
77 92 88 .10
63 45 43 .14
17 12 18 .59
57 8 5 .01
 316 380 716 525 671 .01
(20) 3 (4) 11 (10) .04
2 2 0 .91
(20) 9 (12) N/A .38
ion; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular
ry bypass grafting; IQR, interquartile range; ICD, implantable cardioverter-outc
62
18
6.8
5.7
157
248
6
6
fract
ry arteearly risk for ventricular arrhythmias after LVR. Among
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inducible sustained ventricular arrhythmias. In patients with
ICDs, 15% had either sudden cardiac death or appropriate
ICD shocks. ICD therapies tended to occur early, within the
first 60 to 90 days. With the strategy of early EP study, ICD
implantation, or both, the overall incidence of sudden death
was less than 1%.
The low incidence of sudden death is remarkable be-
cause these patients had very advanced heart failure due to
ischemic cardiomyopathy, with a mean LVEF of 22%. As
such, they were at high risk for the development of ventric-
ular arrhythmias. Most had limiting heart failure symptoms
(68% New York Heart Association class III/IV before sur-
gery). Of interest, New York Heart Association class IV
heart failure is usually considered a contraindication to ICD
implantation. Furthermore, sudden death (assumed to be
due to arrhythmia) occurred in 7 of 147 patients who un-
derwent left ventricular aneurysm repair at single center and
who were followed up for a median on 3.7 years. This rate
indicates a very high propensity for lethal ventricular ar-
rhythmias in this patient population.13 Of note, none of
these patients received antiarrhythmic therapy.
At present, there are no recommendations regarding the
use and timing of ICDs in patients undergoing LVR. Nearly
Figure 2. Kaplan-Meier survival curve according to groups (cen-
sored for cardiac transplantation).
TABLE 2. Causes of death after left ventricular reconstruc
Group
Total
deaths
Sudden
death
Cardiac
dysfunctio
1 6 1 5
2 3 0 2
3 11 0 7*Cardiac dysfunction includes death from myocardial infarction, progressive he
1254 The Journal of Thoracic and Cardiovascular Surgery ● Novall (85%) patients had an LVEF of 30% or less and, as such,
would fit MADIT II criteria for prophylactic ICD implan-
tation for primary prevention of sudden cardiac death.10
However, patients were excluded from MADIT II if they
were within 3 months of CABG. In the LVR population
studied here, 67% of those who received ICD therapies had
their first therapy within 90 days after LVR. Had we waited
3 months before implantation of an ICD, these patients may
have been at a significant risk for potentially preventable
sudden cardiac death. The opportunity to improve survival
by the early application of EP testing, ICD implantation, or
both in patients undergoing LVR is highly relevant, because
performance of this procedure is growing. The strategy we
used in group 2 of early ICD implantation or EP-guided
ICD implantation seemed successful in view of the low
incidence of sudden cardiac death observed in this group.
The effects of EP studies and ICD therapies have not
been analyzed in other studies of LVR, including a large
observational study (Surgical Anterior Ventricular Endocar-
dial Restoration) of 439 patients undergoing LVR. In this
study, which included 114 patients from our institution,
survival was 84% at 18 months.14 It is of interest that the
population presented in the current study had a lower LVEF
(22% vs 29%) yet had a similar survival.
Whether EP risk stratification or ICD implantation with-
out EP testing is warranted before discharge after LVR has
been debated. In light of MADIT II, the utility of EP studies
in patients with coronary disease and ejection fractions less
than 30% has been questioned, because the benefit of ICD
implantation occurs irrespective of EP testing. In the pop-
ulation presented here, however, negative EP studies were
predictive of good 30-day survival. No patient with a neg-
ative EP study died within 30 days (2 died within 90 days).
Of the 46 patients in group 3 who did not have an EP study,
however, 8 died during follow-up (3 during the first 90 days
and none before 30 days). Furthermore, delaying EP risk
stratification or ICD implantation until 3 months after sur-
gery could, arguably, have resulted in avoidable sudden
cardiac deaths.
In this study, long-term survival in patients with positive
EP studies was similar to that in patients with negative EP
studies. This finding may reflect the protective effect of ICD
implantation in patients with positive studies, thus indicat-
ing effective risk stratification and treatment for high-risk
Malignancy
Respiratory
failure Unknown
0 0 0
0 1 0
2 0 2tion
n*art failure, multiple organ failure, and other cardiac (unspecified) causes.
ember 2005
O’Neill et al Surgery for Acquired Cardiovascular Disease
A
CDpatients. Indeed, a positive EP study was predictive of 8 of
9 ICD therapies delivered in group 2. However, limitations
in the ability of EP studies to stratify risk in this high-risk
population cannot be completely excluded.
Group 1 in this study had the worst survival, despite the
presence of preoperative ICDs. The poorer survival may
have been related to the greater severity of their cardiomy-
opathy, as manifested by larger, less contractile ventricles
and the presence of a preoperative ICD (a marker for a
history of or risk for life-threatening cardiac arrhythmias).
Because most deaths occurred as a result of progressive
myocardial failure, rather than sudden arrhythmic events,
these predictors may be markers of a residual propensity to
develop progressive heart failure. Whether these patients
should undergo LVR is another issue to be addressed by the
STICH trial.
The question of whether LVR increases or decreases the
likelihood of ventricular arrhythmias is complex. Removal
of myocardial scarring may protect from ventricular ar-
rhythmias. However, the resultant ventriculectomy scar may
be proarrhythmic. In Dor and colleagues’15 original descrip-
tion of the procedure, recurrent ventricular arrhythmia was
the indication for operation in 8% of patients. Postoperative
follow-up regarding ventricular arrhythmia events in this
series was unclear. In a larger later series, however, Dor16
(who routinely uses cryoablation and endocardial resection)
reported an 8% incidence of inducible ventricular tachycar-
dia after surgery. In their initial study on the outcome of
LVR, the Reconstructive Endoventricular Original Radius
Elliptical Shape to the Left Ventricle group reported ar-
rhythmic deaths in 4 of 8 late deaths, which occurred in 207
patients who survived to discharge from the hospital after
LVR.17 In a Japanese study of LVR in patients with only
Figure 3. Kaplan-Meier survival curve (censored for cardiac
transplantation) according to electrophysiologic (EP) results.akinetic left ventricular scars, 3 (6%) of 47 died from
The Journal of Thoracicarrhythmic deaths after discharge.18 Mickleborough19 re-
ported a very low incidence of ventricular arrhythmias after
left ventricular aneurysmectomy and a 79% 5-year survival.
By comparison, in the current study, the rate of positive EP
studies was 48 (42%) of 113, and the risk of arrhythmic
events (ICD therapies plus sudden death mortality) in
groups 1 and 2 was 16 (15%) of 104. Nevertheless, the
overall incidence of sudden death was 1 (0.5%) of 217 by
using the current strategy of early risk stratification and/or
ICD implantation when feasible. These issues will be im-
portant to analyze in the ongoing STICH trial, a large
randomized prospective study comparing medical versus
surgical management (with or without LVR) of patients
with ischemic cardiomyopathy.1
Patients undergoing LVR remain at risk for life-threatening
arrhythmias, and EP-guided ICD implantation may result in
improved short-term and intermediate-term survival. Pre-
dictors of ICD therapies included larger left ventricular
dimensions, lower ejection fraction, and lack of concomi-
tant revascularization, thus suggesting that the degree of
myocardial dysfunction may remain a prime indicator of
residual risk for ventricular arrhythmias. Because of the
early risk of arrhythmias in patients after LVR, we suggest
that either early ICD implantation or predischarge EP study
for risk stratification is indicated.
This was an observational study in patients who were
selected as suitable for LVR. It was nonrandomized, and EP
testing was performed at the discretion of the treating phy-
sician. The number of outcome events was small and did not
allow for multivariable modeling. Nevertheless, this study
remains among the largest published series regarding the
outcome of the LVR procedure.In conclusion, patients un-
dergoing LVR remain at significant risk for ventricular
arrhythmias. The time to the first arrhythmic event is short.
Figure 4. Time to first therapy (within 90 days of LVR surgery) in
patients with ICD firings (n  15).Two thirds of first arrhythmic events occurred within the
and Cardiovascular Surgery ● Volume 130, Number 5 1255
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meet MADIT II criteria for prophylactic ICD implan-
tation. The data presented here support the use of early ICD
implantation or EP-guided ICD therapy before hospital
discharge.
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